Compare LPCN & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPCN | HSCS |
|---|---|---|
| Founded | 1997 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 15.8M |
| IPO Year | 2011 | 2022 |
| Metric | LPCN | HSCS |
|---|---|---|
| Price | $2.10 | $4.73 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 31.2K | ★ 135.7K |
| Earning Date | 05-07-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.84 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,976,677.00 | $4,319.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $92.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.81 | $1.63 |
| 52 Week High | $12.37 | $5.25 |
| Indicator | LPCN | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 38.84 | 66.28 |
| Support Level | $2.00 | $1.88 |
| Resistance Level | $2.27 | N/A |
| Average True Range (ATR) | 0.09 | 0.52 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 0.00 | 74.00 |
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare setting, either via the MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via the MyoVista wavECG Device.